Safety and Efficacy of Alprostadil Sterile Powder (S. Po., CAVERJECT®) in Diabetic Patients with Erectile Dysfunction

2000 ◽  
Vol 38 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Yuh-Shyan Tsai ◽  
Johnny Shinn-Nan Lin ◽  
Yung-Ming Lin
Keyword(s):  
Erectile Dysfunction ◽  
Diabetic Patients ◽  
Safety And Efficacy

scholarly journals Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton’s Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial

2021 ◽  
pp. 1-9
Author(s):  
Saddam Al Demour ◽  
Sofia Adwan ◽  
Hanan Jafar ◽  
Reem Rahmeh ◽  
Hussam Alhawari ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Erectile Dysfunction ◽  
Phase 1 ◽  
Wharton’S Jelly ◽  
Secondary Outcome ◽  
Diabetic Patients ◽  
Safety And Efficacy ◽  
Wharton's Jelly

<b><i>Background and Objectives:</i></b> Stem cell therapy is a novel treatment with regenerative ability that can treat erectile dysfunction (ED). This phase 1/2 clinical trial (NCT02945449) using 2 consecutive intracavernous (IC) injections of allogeneic Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) was studied for the first time in the treatment of diabetic patients with ED. The primary outcome was to assess the safety and tolerability, and the secondary outcome was to assess the efficacy of 2 consecutive IC injections of allogeneic WJ-MSCs in diabetic ED. <b><i>Patients and Methods:</i></b> Twenty-two diabetic patients with refractory ED were included. Two consecutive IC injections of allogeneic WJ-MSCs were performed. Tolerability was assessed immediately, and at 24 h, safety was evaluated for 12 months. Efficacy was assessed using International Index of Erectile Function-5 (IIEF-5), Erection Hardness Score (EHS), and Color Duplex Doppler Ultrasound for 12 months. <b><i>Results:</i></b> The procedure was well-tolerated. Minimal and transient adverse events were redness and bruising at the site of injections. There were no patient-reported serious adverse effects. There were significant improvements in IIEF-5, EHS, peak systolic velocity (PSV) basal, and 20-min PSV, all over the follow-up time points in comparison to the baseline. <b><i>Conclusion:</i></b> This is the first human study with proven tolerability, safety, and efficacy of IC injections of allogeneic WJ-MSCs for the treatment of diabetic patients with ED.

The relationship between serum irisin levels and erectile dysfunction in diabetic men (irisin and erectile dysfunction in diabetic patients)

Andrologia ◽  
2021 ◽  
Author(s):  
Şükrü Kumsar ◽  
Özlem Ciğerli ◽  
Eray Hasırcı ◽  
Ali F. Akay ◽  
Levent Peşkircioğlu
Keyword(s):  
Erectile Dysfunction ◽  
Diabetic Patients ◽  
The Relationship

scholarly journals Relation Between Erectile Dysfunction and Silent Myocardial Ischemia in Diabetic Patients: A Multidetector Computed Tomographic Coronary Angiographic Study

2016 ◽  
Vol 4 (3) ◽  
pp. e127-e134 ◽  
Author(s):  
Amr Abdelhamed ◽  
Shin-ichi Hisasue ◽  
Essam A. Nada ◽  
Ali M. Kassem ◽  
Mohammed Abdel-Kareem ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Myocardial Ischemia ◽  
Silent Myocardial Ischemia ◽  
Diabetic Patients ◽  
Angiographic Study ◽  
Computed Tomographic

scholarly journals REAL WORLD SAFETY AND EFFICACY OF SGLT-2 INHIBITORS IN ELDERLY TYPE 2 DIABETIC PATIENTS

2017 ◽  
Vol 1 (suppl_1) ◽  
pp. 148-148
Author(s):  
C. Trescoli Serrano ◽  
C.J. Fajardo ◽  
J. Arazo ◽  
F.J. Tarazona-Santabalbina
Keyword(s):  
Real World ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Safety And Efficacy ◽  
Type 2 Diabetic

Platelet Indices as a marker for early prediction of erectile dysfunction in diabetic patients

Andrologia ◽  
2018 ◽  
Vol 51 (1) ◽  
pp. e13163 ◽  
Author(s):  
Moustafa A. El Taieb ◽  
Eisa M. Hegazy ◽  
Salah M. Maklad ◽  
Reham Khairy
Keyword(s):  
Erectile Dysfunction ◽  
Diabetic Patients ◽  
Early Prediction ◽  
Platelet Indices

scholarly journals Safety and efficacy of bivalirudin in diabetic acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
A Golam Mostofa ◽  
T Parvin ◽  
R Masum Mandal ◽  
S Ali Ahsan ◽  
R Afrin
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndrome ◽  
Major Bleeding ◽  
Guide Wire ◽  
Coronary Intervention ◽  
Diabetic Patients ◽  
Safety And Efficacy ◽  
Coronary Syndrome ◽  
Percutaneous Coronary ◽  
Hemorrhagic Complications

Abstract Background Prevention of hemorrhagic complications has emerged as a priority in patients undergoing Percutaneous Coronary Intervention (PCI) in addition to suppressing thrombotic complications. This goal is challenging to achieve in diabetic Acute Coronary Syndrome (ACS) patients as Diabetes Mellitus (DM) itself is a prothrombotic state with more pronounced vascular injury response and have a worse outcome after PCI compared with non-diabetic patients. In patients with ACS, Bivalirudin has been shown to result in similar rates of composite ischemia as Heparin plus GPI (GP IIb /IIIa inhibitor), while significantly reducing major bleeding and has received class I recommendation for PCI by American College of Cardiology (ACC 2013). Whether Bivalirudin is safe and effective specially in diabetic ACS patients undergoing PCI, as compared with Heparin (UFH) monotherapy, is unknown. Purpose To determine and compare the incidence of in-hospital and 30-day hemorrhagic complications and major adverse cardiac events (MACEs) as evidence of safety and efficacy using Bivalirudin versus Heparin in diabetic ACS patients undergoing PCI. Methods 218 diabetic ACS patients (age&gt;18 years and ≤75 years) who underwent PCI from May 2018 to April 2019 at University Cardiac Centre, BSM Medical University, Dhaka, Bangladesh were randomly assigned to have UFH or Bivalirudin. Before the guide wire crossed the lesion, 111 patients in the UFH group received a bolus of 70–100 U/kg (targeted activated clotting time, ACT: 200–250 s). 107 patients in the Bivalirudin group received a loading dose of 0.75 mg/kg, followed by an infusion of 1.75 mg/kg/h for up to 4 hours. Dual antiplatelet (DAPT) loading as Aspirin 300 mg plus P2Y12 inhibitors (Clopidogrel 600 mg or Prasugrel 60 mg or Ticagrelor 180 mg) was given in all patients before the procedure. The maintenance dose of DAPT was continued for at least one month and patients were followed telephonically up to 30 days. The outcome measures were in-hospital and 30-day hemorrhagic complications and MACEs [death, MI, target vessel revascularization (TVR) and stroke]. Results Patients treated with Bivalirudin compared with Heparin had a significantly lower in-hospital incidence of QMI (0% vs. 6%; p=0.03) and major bleeding (0% vs. 7%; p=0.02). However, the incidence of cardiac death, stent thrombosis, TVR were no differences between two groups (p&gt;0.05). There was only one NQMI in the Bivalirudin group as opposed to 8% in the Heparin group in 30 days following stenting (p=0.04). Conclusion In diabetic ACS patients undergoing PCI, Bivalirudin is safe and effective as it reduces immediate and short-term hemorrhagic complications as well as MACEs as compared with Heparin. FUNDunding Acknowledgement Type of funding sources: None.

Sign in / Sign up

Export Citation Format

Share Document